A personalized mRNA cancer vaccine has met its primary end point in a pivotal phase 3 melanoma trial, offering new evidence that individualized neoantigen therapy could help reduce the risk of recurrence after surgery.¹

In the INTerpath-001 trial, intismeran autogene, developed by Merck and Moderna, significantly improved recurrence-free survival (RFS) when added to pembrolizumab (Keytruda) compared with Keytruda alone in patients with completely resected stage IIB-IV cutaneous melanoma. The combination also significantly improved distant metastasis-free survival (DMFS), a key secondary end point.^1,2

The trial enrolled 1137 patients, but what makes the results particularly notable is the treatment itself: intismeran is not an off-the-shelf cancer vaccine; each treatment is designed around the molecular profile of an individual patient’s tumor. Tumor mutations are analyzed to identify neoantigens, and the resulting mRNA vaccine can encode up to 34 patient-specific neoantigens intended to generate an immune response against the cancer.^1,3

That means two patients with melanoma may receive two different versions of intismeran, each designed around the mutations found in their own tumor.

The interim phase 3 analysis showed statistically significant and clinically meaningful improvements in both RFS and DMFS.¹ Detailed results have not yet been released, and overall survival remains under evaluation. Merck and Moderna plan to present the findings at an upcoming international medical meeting and share the data with regulatory authorities.¹

The results also strengthen findings seen earlier in the development of intismeran. Five-year follow-up from the phase 2b KEYNOTE-942/mRNA-4157-P201 trial showed that intismeran plus Keytruda reduced the risk of recurrence or death by 49% compared with Keytruda alone.^1,2 No new safety signals were identified in INTerpath-001, and the safety profile remained consistent with previous studies of the combination.¹

For patients with high-risk melanoma, the implications are difficult to overlook. Surgery may leave a patient with no evidence of disease while the risk of recurrence persists. INTerpath-001 raises the possibility of adding another layer of protection after surgery, one developed not simply for melanoma, but around the individual biology of a patient’s melanoma.

Intismeran remains investigational, and the complete phase 3 data will be important in determining just how substantial that benefit may be. But the positive results move individualized cancer vaccination another step closer to clinical practice.

And melanoma may be only part of the story. Merck and Moderna are evaluating intismeran across a broader clinical development program that includes non–small-cell lung cancer, bladder cancer and renal-cell carcinoma.^1,3 If the approach continues to demonstrate benefit, the implications could reach well beyond melanoma.

References

1. Merck and Moderna announce Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met endpoints of recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in patients with resected melanoma. Merck. Published August 2026. Accessed August 19, 2026. www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/
2. Moderna and Merck say melanoma vaccine succeeded in large trial. CNN. Published August 2026. Accessed August 19, 2026. www.cnn.com/2026/08/19/health/moderna-merck-mrna-melanoma-vaccine
3. Merck, Moderna’s mRNA cancer vaccine shows promise in melanoma trial. MedCity News. Published August 2026. Accessed August 19, 2026. https://medcitynews.com/2026/08/merck-moderna-mrna-cancer-vaccine-neoantigen-intismeran-melanoma-adjuvant-mrk/